April 18, 2024
Stocks & Bonds
[EQUITIES] ‘KUP remains strong on the back of new IMDs’
[THE INVESTOR] Korea United Pharm will post record earnings in the fourth quarter last year on the back of brisk sales of Gastin CR, a new drug released in the previous quarter, said Shinhan Financial Investment on Jan. 16.
The securities firm raised the target price to 22,000 won (US$18.60) from 20,000 won saying that it will continue the upturn, thanks to the incrementally modified drug that enhances gastrointestinal motility.
Its fourth-quarter revenue will reach 46.4 billion won and operating profit 7.2 billion won, up 10.7 percent and 10.3 percent on-year, respectively, said analyst Bae Gi-dal.
“The sales portion of new IMDs including Cilostan CR and Gastin CR will increase to 18.5 percent from 14.8 percent last year,” added the analyst, projecting the pharmaceutical company’s 2017 revenue to reach 195 billion won and operating profit 30.7 billion won, up 10.1 percent and 15.4 percent on-year, respectively.
By Hwang You-mee (glamazon@heraldcorp.com)
The securities firm raised the target price to 22,000 won (US$18.60) from 20,000 won saying that it will continue the upturn, thanks to the incrementally modified drug that enhances gastrointestinal motility.
Its fourth-quarter revenue will reach 46.4 billion won and operating profit 7.2 billion won, up 10.7 percent and 10.3 percent on-year, respectively, said analyst Bae Gi-dal.
“The sales portion of new IMDs including Cilostan CR and Gastin CR will increase to 18.5 percent from 14.8 percent last year,” added the analyst, projecting the pharmaceutical company’s 2017 revenue to reach 195 billion won and operating profit 30.7 billion won, up 10.1 percent and 15.4 percent on-year, respectively.
By Hwang You-mee (glamazon@heraldcorp.com)
